COVID-19 ground zero boasts low SARS-CoV-2 seroprevalence
Seroprevalence of antibodies against SARS-CoV-2 remains low in Wuhan, China, despite being the site where the novel coronavirus disease (COVID-19) was first detected, a recent study has found.